Printer Friendly

STERLING WINTHROP PHARMACEUTICALS RESEARCH DIVISION REORGANIZED FOR ENHANCED PORTFOLIO DEVELOPMENT AND FOCUS

 STERLING WINTHROP PHARMACEUTICALS RESEARCH DIVISION REORGANIZED
 FOR ENHANCED PORTFOLIO DEVELOPMENT AND FOCUS
 NEW YORK, April 30 /PRNewswire/ -- Sterling Winthrop Inc. recently announced a significant reorganization of the management structure of its Pharmaceuticals Research Division (SWPRD), as a further step in the achievement of its goal to be a dynamic leader in pharmaceutical R&D.
 According to Eugene Cordes, Ph.D., president, Pharmaceuticals Research Division, the reorganization will markedly strengthen the company's portfolio development and management.
 "I am very pleased to announce these management changes within the Pharmaceuticals Research Division," commented Cordes. The reorganization covers three areas: resources, strategy, and the creation of the Office of the President. "Not only does it recognize the significant contributions of many of our people, but as a result, our resources will be more closely focused on our core research areas."
 Resources
 Jack Dean, Ph.D., has been promoted to the new position of executive vice president, development. Reporting to Dean will be drug regulatory affairs, clinical research, pharmaceutical sciences, drug metabolism and analytical sciences groups. Dean will also continue to be responsible for drug safety assessment. Scientific activities at Sterling Winthrop's Alnwick Research Center in England and Dijon Research Center in France will also report to Dean.
 Alastair Ross has been named to the new position of senior vice president, administration. Reporting to Ross are Gene Bolster, who assumes the new position of senior director, operations; Judy Camp, director, finance; and Gary Stephens, project director for Sterling Winthrop's new research center at Upper Providence Township, Pa. Research centers in Alnwick and Dijon will report to Ross for facilities and finance issues.
 In addition, a new position, vice president, information science, has been created to encompass the increasingly sophisticated information sciences and technologies which are central to the operations of the division. An appointment to this position will be announced in the future.
 Strategy
 To build and sustain Sterling Winthrop's portfolio of discovery and development projects, three new vice president positions responsible for research strategy have been created.
 Denis Bailey, Ph.D., has been named executive vice president, diagnostic imaging. Edward Bradley, M.D., will serve as senior vice president, oncology, and Larry Sternson, Ph.D., has been named senior vice president, therapeutics. They will guide the company's research efforts in the areas of diagnostic imaging, cardiovascular medicine, viral diseases, cancer, immune-based diseases and inflammation and diseases of the central nervous system.
 Office of the President
 Cordes also announced the creation of the Office of the President. Under his guidance, this office will be responsible for a number of critical activities within SWPRD, including management of the R&D activities with regard to the recent alliance between Sterling Winthrop and Elf Sanofi, headquartered in Paris. Within the Office of the President, Nancy Durst will serve as vice president, strategic issues; Jean Legros will serve as executive director, science coordination; and Pat Singer will serve as senior director, project planning & management. This new team will report directly to Cordes.
 SWPRD management is currently located in Malvern, Pa., with facilities also in Rensselaer, N.Y. The division will begin to occupy a new $300 million state-of-the-art research facility in Upper Providence Township, Pa. at the end of this year.
 Guided by its strategic framework and values, the people of Sterling Winthrop are a worldwide team committed to creating distinctive solutions for the needs of mankind in pharmaceuticals and consumer health products. With headquarters in New York, the company is a subsidiary of the Eastman Kodak Company (NYSE: EK).
 -0- 4/30/92
 /CONTACT: Diane Iselin, 212-907-2341, or Terry Kelley, 212-907-3009, both of Sterling Winthrop/
 (EK) CO: Sterling Winthrop Inc. ST: New York IN: MTC SU: RCN


GK-OS -- NY049 -- 4884 04/30/92 11:35 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1992
Words:618
Previous Article:'WHEELS OF MICHIGAN' STREET CLOSINGS
Next Article:PENNSYLVANIA TO HOST ANNUAL REGIONAL MEETING OF TRANSPORTATION OFFICIALS IN PHILADELPHIA


Related Articles
STERLING WINTHROP AND BIOMIRA SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
BIOMIRA AND STERLING WINTHROP SIGN AGREEMENTS FOR THE DEVELOPMENT OF ANTIBODY-BASED CANCER PRODUCTS
CONTRAST MEDIA RESEARCH ALLIANCE FORMED BY STERLING WINTHROP AND STANFORD UNIVERSITY
KODAK & STERLING WINTHROP DESCRIBE SUCCESSES SINCE ACQUISITION
STERLING WINTHROP ANNOUNCES MAY 10 DEDICATION OF PHARMACEUTICAL R&D CENTER IN UPPER PROVIDENCE TOWNSHIP, PA.; PAULING AND KELLEY TO SPEAK
STERLING WINTHROP DEDICATES PHARMACEUTICALS RESEARCH AND DEVELOPMENT CENTER IN UPPER PROVIDENCE TOWNSHIP, PA.
STERLING WINTHROP SCIENCE FELLOWSHIP PROGRAM UNVEILED AT DEDICATION OF PHARMACEUTICAL RESEARCH DIVISION R&D CENTER IN UPPER PROVIDENCE TOWNSHIP
BRISTOL-MYERS SQUIBB, STERLING WINTHROP INC. AND ELF SANOFI ANNOUNCE CARDIOVASCULAR DEVELOPMENT EFFORT
STERLING WINTHROP AND ELF SANOFI ANNOUNCE JOINT DEVELOPMENT AND COMMERCIALIZATION OF TWO NEW AGENTS WITH BRISTOL-MYERS SQUIBB
CLOSING COMPLETED, SANOFI NAMES MANAGEMENT TEAM FOR PHARMACEUTICAL DIVISION

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters